Wikipedia

User:Mr. Ibrahem/Ponesimod

< User:Mr. Ibrahem
Mr. Ibrahem/Ponesimod
Clinical data
Trade namesPonvory
Other namesACT-128800
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Metabolism2 main metabolites
Elimination half-life31–34 hrs[5]
ExcretionFeces (57–80%, 26% unchanged), urine (10–18%)[6]
Identifiers
  • (2Z,5Z)-5-{3-Chloro-4-[(2R)-2,3-dihydroxypropoxy]benzylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one
Chemical and physical data
FormulaC23H25ClN2O4S
Molar mass460.97 g·mol−1
3D model (JSmol)
  • CCC/N=C\1/N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
  • InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1
  • Key:LPAUOXUZGSBGDU-STDDISTJSA-N

Ponesimod, sold under the brand name Ponvory, is a medication used to treat multiple sclerosis (MS).[3] Specifically it is used for the relapsing forms including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease.[7][3] It is taken by mouth.[3]

Common side effects include upper respiratory tract infection, liver inflammation, and high blood pressure.[3] Other side effects may include infection, slow heart rate, breathing problems, and skin cancer.[3] Use during pregnancy may harm the baby.[3] It is a [[sphingosine 1-phosphate receptor modulator which decreases the activity of T and B cells.[3][7]

Ponesimod was approved for medical use in the United States and Europe in 2021.[3][7] In the United Kingdom 4 weeks of treatment costs the NHS about £1100 as of 2022.[8] In the United States this amount costs about 7,900 USD.[9]

References edit

  1. ^ a b "Ponvory APMDS". Therapeutic Goods Administration (TGA). 24 March 2022. Retrieved 4 April 2022.{{cite web}}: CS1 maint: url-status (link)
  2. ^ "Summary Basis of Decision (SBD) for Ponvory". Health Canada. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  3. ^ a b c d e f g h i j k l "Ponvory- ponesimod tablet, film coated Ponvory- ponesimod kit". DailyMed. Archived from the original on 21 January 2022. Retrieved 31 March 2021.
  4. ^ "Ponvory EPAR". European Medicines Agency (EMA). 24 March 2021. Archived from the original on 19 March 2022. Retrieved 18 December 2021.
  5. ^ Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J (February 2014). "Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration". Journal of Clinical Pharmacology. 54 (2): 179–88. doi:10.1002/jcph.244. PMID 24408162. S2CID 38041837.
  6. ^ Reyes M, Hoch M, Brossard P, Wagner-Redeker W, Miraval T, Dingemanse J (February 2015). "Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 45 (2): 139–49. doi:10.3109/00498254.2014.955832. PMID 25188442. S2CID 23905158.
  7. ^ a b c "European Medicines Agency Approval of Ponesimod". Archived from the original on 2021-08-04. Retrieved 2021-08-04.
  8. ^ "Ponesimod". SPS - Specialist Pharmacy Service. 12 January 2016. Archived from the original on 20 January 2022. Retrieved 31 October 2022.
  9. ^ "Ponvory". Archived from the original on 31 October 2022. Retrieved 31 October 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ponesimod&oldid=1214441540"